Simulations Plus stock: Johnson Fistel investigates Simulations Plus stock over 2025 guidance

Published on 10/24/2026 at 01:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Johnson Fistel cites USD 76 million to USD 80 million in fiscal 2025 guidance. The estimated Q4 report for Simulations Plus stock is October 29, 2026.

Private-company transition and investor review

Johnson Fistel announced its Simulations Plus investigation on October 22, 2026, citing fiscal 2025 guidance of USD 76 million to USD 80 million.
The Altaris merger closed on October 6, 2026, paying shareholders USD 18.50 per share.
MarketBeat lists an estimated Q4 2026 report for October 29, 2026.

SLP, US8292141053, Illustration mit AI erstellt.

Simulations Plus (ISIN US8292141053) faced a new investor investigation on October 22, 2026, after GlobeNewswire reported that Johnson Fistel was examining historical guidance cuts and accounting disclosures. The release cited fiscal 2025 revenue guidance of USD 76 million to USD 80 million.

The company had already crossed from public ownership into private ownership earlier in October. Simulations Plus said on October 6, 2026, that affiliates of Altaris completed the acquisition and paid eligible shareholders USD 18.50 per share in cash.

Three dates changed the ownership story

The chronology is clear. On June 16, 2026, Simulations Plus originally announced the transaction, which carried consideration of USD 18.50 per share. On October 6, 2026, the merger closed and the company requested that Nasdaq cease trading its common shares. On October 22, 2026, Johnson Fistel announced its investigation, citing the historical USD 76 million to USD 80 million fiscal 2025 revenue guidance.

What does the USD 18.50 payout mean?

The payout became the final public-market reference for eligible shareholders, while the company continued under Altaris ownership. The official merger release also said Simulations Plus would be combined with Chemical Computing Group, creating a broader platform for drug discovery, modeling and development.

Reporting dates remain on the calendar

MarketBeat lists an estimated Q4 2026 earnings announcement for October 29, 2026, after the market close, followed by a conference call on October 30, 2026, at 4:00 p.m. ET. The same page places the prior report on July 9, 2026, when revenue was USD 21.89 million and earnings per share were USD 0.30, versus consensus earnings per share of USD 0.2325.

Private ownership sets the next frame

The October 16, 2026 Form 15 filing stated that Simulations Plus had one holder of record and was seeking to terminate its reporting obligations. The SEC filing dated October 6, 2026 documented the request to suspend the Nasdaq listing. For investors, the investigation is therefore a historical review of a public company whose merger has already changed the ownership structure.